TY - JOUR
T1 - Nonalcoholic Fatty Liver Disease and Cardiovascular Risk
T2 - A Scientific Statement From the American Heart Association
AU - American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Hypertension; Council on the Kidney in Cardiovascular Disease; Council on Lifestyle and Cardiometabolic Health; and Council on Peripheral Vascular Disease
AU - Duell, P. Barton
AU - Welty, Francine K.
AU - Miller, Michael
AU - Chait, Alan
AU - Hammond, Gmerice
AU - Ahmad, Zahid
AU - Cohen, David E.
AU - Horton, Jay D.
AU - Pressman, Gregg S.
AU - Toth, Peter P.
PY - 2022/6/1
Y1 - 2022/6/1
N2 - Nonalcoholic fatty liver disease (NAFLD) is an increasingly common condition that is believed to affect >25% of adults worldwide. Unless specific testing is done to identify NAFLD, the condition is typically silent until advanced and potentially irreversible liver impairment occurs. For this reason, the majority of patients with NAFLD are unaware of having this serious condition. Hepatic complications from NAFLD include nonalcoholic steatohepatitis, hepatic cirrhosis, and hepatocellular carcinoma. In addition to these serious complications, NAFLD is a risk factor for atherosclerotic cardiovascular disease, which is the principal cause of death in patients with NAFLD. Accordingly, the purpose of this scientific statement is to review the underlying risk factors and pathophysiology of NAFLD, the associations with atherosclerotic cardiovascular disease, diagnostic and screening strategies, and potential interventions.
AB - Nonalcoholic fatty liver disease (NAFLD) is an increasingly common condition that is believed to affect >25% of adults worldwide. Unless specific testing is done to identify NAFLD, the condition is typically silent until advanced and potentially irreversible liver impairment occurs. For this reason, the majority of patients with NAFLD are unaware of having this serious condition. Hepatic complications from NAFLD include nonalcoholic steatohepatitis, hepatic cirrhosis, and hepatocellular carcinoma. In addition to these serious complications, NAFLD is a risk factor for atherosclerotic cardiovascular disease, which is the principal cause of death in patients with NAFLD. Accordingly, the purpose of this scientific statement is to review the underlying risk factors and pathophysiology of NAFLD, the associations with atherosclerotic cardiovascular disease, diagnostic and screening strategies, and potential interventions.
KW - AHA Scientific Statements
KW - cardiovascular diseases
KW - diabetes mellitus
KW - hepatocytes
KW - hypertriglyceridemia
KW - insulin resistance
KW - metabolic syndrome
KW - nonalcoholic fatty liver disease
KW - triglycerides
UR - http://www.scopus.com/inward/record.url?scp=85131105897&partnerID=8YFLogxK
U2 - 10.1161/ATV.0000000000000153
DO - 10.1161/ATV.0000000000000153
M3 - Review article
C2 - 35418240
AN - SCOPUS:85131105897
SN - 1079-5642
VL - 42
SP - e168-e185
JO - Arteriosclerosis, thrombosis, and vascular biology
JF - Arteriosclerosis, thrombosis, and vascular biology
IS - 6
ER -